Secondary pooled analysis of 2 phase 3 trials (2190 patients with prostate cancer): apalutamide's effect on overall survival did not differ by race (interaction p = .46), and race was not associated with survival among apalutamide-treated patients.
Secondary analysisn = 2,190
Gebrael et al. Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials